Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor. Molecular Cancer Therapeutics, 2023; 22 ...

The focus of this month’s blog post is a discussion of malignant peripheral nerve sheath tumors (MPNSTs), which represent one of the few potentially life-threatening complications of neurofibromatosis ...

Peripheral nerve sheath tumors (PNSTs), particularly schwannomas, are the most common type of nerve tumors. These tumors arise from the protective sheath surrounding peripheral nerves and can ...

Among the peripheral nerve sheath tumors (PNSTs) evaluated, which included 20 MPNSTs and two neurofibromas, only 9% showed reactivity for pan-cytokeratin, 18% for CK7, and none for CK19. [These ...

Bin Liu, Wang Xin, Jian-Rong Tan, Rui-Ping Zhu, Ting Li, Dan Wang, Sha-Sha Kan, Ding-Kui Xiong, Huan-Huan Li, Meng-Meng Zhang, Huan-Huan Sun, William Wagstaff, Chan Zhou, Zhi-Jian Wang, Yao-Guang ...

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) - soft tissue tumors that are stubbornly resistant to chemotherapy and radiation ...

Abstract Purpose: To identify target genes of clinical significance for patients with malignant peripheral-nerve sheath tumor (MPNST), an aggressive cancer for which no consensus therapy exists.

Next, I’d like to address the issue of atypical neurofibromas and their potential to become malignant peripheral nerve sheath tumors (MPNST), probably the most feared complication of NF1. Occurring in ...

Cortes-Ciriano, I., et al. (2023) Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer ...

Background: Malignant peripheral nerve sheath tumors (MPNST) constitute a group of malignant tumors that arise from schwann cells of the peripheral nerve sheath. Neurofibromatosis type 1 (NF1), an ...

Researchers from Johns Hopkins University and affiliated organizations have published details on the discovery and preclinical characterization of a purine antimetabolite, Pro-905, which is being ...

Researchers from Qualigen Therapeutics Inc. and University of Louisville presented the discovery and preclinical evaluation of a novel pan-RAS inhibitor, F3-8-60, being developed for the treatment of ...